ArticleCancer gene therapy2025
The activated tyrosine kinase ACK1 by multiple receptor tyrosine kinases promotes proliferation and invasion of mesothelioma via regulation of PI3K/AKT/mTOR and RAF/MAPK signaling pathways.
Article in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Activation of the receptor tyrosine kinases (RTKs) EGFR, MET, and AXL has been described in subsets of mesothelioma, suggesting that tyrosine kinases (TKs) might represent therapeutic targets in this chemotherapy resistant and highly lethal cancer. In the present study, activated TKs were identified in mesothelioma cells by phosphotyrosine immunoaffinity purification and tandem mass spectrometry, and biological functions were evaluated. The results showed that non-RTK activated-CDC42 kinase 1 (ACK1) was highly expressed and activated in 8 of 9 mesothelioma cell lines and 15 of 18 mesothelioma biopsies, but not in normal mesothelial cells. This ACK1 activation was in turn driven by the collective activation of EGFR, MET, and AXL. ACK1 inactivation by either a small molecule inhibitor (AIM-100) or RNAi had anti-proliferative, anti-migration, and pro-apoptotic effects in four mesothelioma cultures due to G1 arrest and xenograft model. These responses resulted from inhibition of the PI3K/AKT/mTOR and RAF/MAPK pathways, inhibition of cyclin A and cyclin D1, and up-regulation of cell cycle checkpoints TP53, CDKN1A (p21), and CDKN1B (p27). Combination treatment with AIM-100, cisplatin (CIS), and pemetrexed (PEM) had greater impact on mesothelioma response (apoptosis, proliferation arrest, and inhibition of migration and invasion) compared to administering only one or two of these agents. The current findings identify ACK1 as a single downstream target that can be inhibited to stymie these multiple receptor tyrosine kinase (EGFR, MET, and AXL) oncogenic programs in mesothelioma, and highlight that ACK1 inhibition, potentially in combination with PEM and CIS, warrants evaluation as a therapeutic strategy in mesothelioma.
Indexed as
Identifiers
40247024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.